• Erastin as a Ferroptosis Inducer: Optimized Workflows & Inno

  2026-05-06

  Erastin, a signature ferroptosis inducer from APExBIO, empowers precise dissection of iron-dependent cell death in RAS/BRAF-mutant cancer models. This article delivers advanced protocols, troubleshooting insights, and expert guidance for integrating Erastin into cutting-edge cancer biology research.

• Dimethyloxalylglycine (DMOG): Technical Guide for Hypoxia Mo

  2026-05-05

  Dimethyloxalylglycine (DMOG) enables controlled stabilization of hypoxia-inducible factors for research into oxygen sensing, hypoxia signaling, and inflammation pathways. It is not suitable for diagnostic or therapeutic use, and researchers should follow strict solubility and storage protocols to ensure reproducibility. This article details DMOG's technical use, protocol parameters, workflow setup, and common troubleshooting strategies.

• Cefiderocol vs. Cefepime: Resistance in European Enterobacte

  2026-05-05

  This study provides the first large-scale, head-to-head comparison of cefiderocol and multiple β-lactam/β-lactamase inhibitor combinations—including novel agents—against Enterobacterales isolates from European hospitals. The findings clarify susceptibility patterns among highly resistant strains, informing both antimicrobial stewardship and research model selection.

• Phosphoproteomic Adaptation to Chronic Cabozantinib in RCC C

  2026-05-04

  This study delineates how acute and chronic Cabozantinib (XL184) exposure differentially remodels phosphorylation signaling in renal cell carcinoma (RCC) cells. Quantitative phosphoproteomics reveal timescale-dependent adaptation, with implications for understanding kinase inhibitor resistance and guiding experimental design in cancer research.

• TSPAN18–STIM1 Axis Drives Bone Metastasis in Prostate Cancer

  2026-05-04

  Zhou et al. reveal that TSPAN18 enhances bone metastasis in prostate cancer by stabilizing STIM1 and amplifying Ca2+ signaling. Their mechanistic insights highlight a novel regulatory pathway and propose TSPAN18 as a potential target for limiting metastatic progression.

• Applied Use Cases of 4μ8C in ER Stress and Hypoxia Research

  2026-05-03

  4μ8C (7-hydroxy-4-methyl-2-oxochromene-8-carbaldehyde) is a precise tool for dissecting the unfolded protein response, enabling reproducible results in hypoxia and ER stress signaling studies. Discover optimized protocols, troubleshooting guidance, and advanced applications that set this selective IRE1 RNase inhibitor apart in cancer research.

• DMXAA (Vadimezan): Applied Workflows for Tumor Vasculature D

  2026-05-02

  DMXAA (Vadimezan) stands out as a potent apoptosis inducer in tumor endothelial cells, driving tumor necrosis via simultaneous inhibition of DT-diaphorase and VEGFR2 signaling. This article offers actionable protocols, troubleshooting strategies, and insights from the latest endothelial immune signaling research to empower advanced cancer biology experiments.

• Carbapenemase Gene Dynamics in CREC: Insights from Guangdong

  2026-05-01

  This study characterizes carbapenemase-encoding gene (CEG) carriage and transmission in carbapenem-resistant Enterobacter cloacae (CREC) from eight Guangdong hospitals during the COVID-19 pandemic. The findings highlight high plasmid-borne blaNDM-1 prevalence, multidrug resistance, and efficient gene transfer, offering key context for resistance mechanism research.

• Caffeine in Modern Research: Mechanistic Insights and Transl

  2026-05-01

  Explore the multifaceted research applications of caffeine (1,3,7-trimethylpurine-2,6-dione), with a unique focus on its mechanistic action and experimental design. This article provides advanced guidance for leveraging caffeine in metabolic, cancer, and obesity models.

• Omeprazole (A2845): H+,K+-ATPase Inhibitor for Gastric Acid

  2026-04-30

  Omeprazole (SKU A2845) provides a high-purity, well-characterized H+,K+-ATPase inhibitor for research on gastric acid secretion and antiulcer mechanisms. It is optimized for use in gastric acid-related disorder models but is not suitable for diagnostic or clinical applications. Appropriate handling and workflow setup are critical for reproducible results.

• Panobinostat Disrupts Epigenetic Maintenance in MLL-ALL Mode

  2026-04-30

  This study demonstrates that panobinostat, a histone deacetylase inhibitor, exhibits potent anti-leukaemic activity in MLL-rearranged acute lymphoblastic leukaemia (ALL) by targeting the RNF20/RNF40/WAC-mediated H2B ubiquitination axis. The findings provide mechanistic insight into the vulnerability of MLL-ALL to epigenetic perturbation, supporting further development of targeted therapies for aggressive infant leukaemia.

• Aprotinin: Applied Strategies for Fibrinolysis Inhibition in

  2026-04-29

  Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI) delivers reliable, reversible serine protease inhibition, empowering bench scientists to precisely modulate fibrinolysis and inflammation across surgical and molecular workflows. This guide details hands-on protocol enhancements, troubleshooting strategies, and translational insights, bridging evidence from recent transcriptomic profiling to cardiovascular and inflammation models.

• BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Guidan

  2026-04-29

  BFH772 is a highly selective VEGFR2 inhibitor designed for precise modulation of VEGFR2-mediated angiogenesis, especially in tumor model research. It is not suitable for workflows requiring water-soluble compounds or broad-spectrum kinase inhibition due to its defined selectivity and solubility profile.

• miR-18a/ALOXE3 Axis Regulates Ferroptosis and Migration in G

  2026-04-28

  This study identifies the miR-18a/ALOXE3 regulatory axis as a critical modulator of ferroptosis and migration in glioblastoma (GBM) cells. By demonstrating that miR-18a downregulates ALOXE3, thereby suppressing ferroptotic cell death and enhancing tumor cell migration, the research highlights a previously unappreciated mechanism underlying GBM progression and suggests new therapeutic targets.

• BFH772 (VEGFR2 inhibitor): Technical Protocols and Use Guide

  2026-04-28

  BFH772 is a highly selective VEGFR2 inhibitor designed for research targeting VEGFR2-mediated angiogenesis, particularly in tumor models. It should not be used in workflows requiring water solubility or broad kinase inhibition due to its defined selectivity and solubility profile.

8680 records 14/579 page Previous Next First page 上5页 1112131415 下5页 Last page